Merus NV (MRUS) has disclosed a new risk, in the Corporate Activity and Growth category.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Merus NV faces significant business risks due to potential delays or failure in completing its transaction with Genmab A/S. The uncertainty surrounding the completion of the Transactions could adversely impact Merus NV’s share price, financial condition, and operational prospects. Additionally, the company may incur substantial costs, face negative publicity, and experience difficulties in maintaining key relationships and attracting talent. The market’s perception of the likelihood of the Transactions’ success could further lead to fluctuations in the company’s share price.
The average MRUS stock price target is $97.71, implying 3.00% upside potential.
To learn more about Merus NV’s risk factors, click here.